Cargando…

Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial

Objectives To study the effect of insulin treatment in combination with metformin or an insulin secretagogue, repaglinide, on glycaemic regulation in non-obese patients with type 2 diabetes. Design Randomised, double blind, double dummy, parallel trial. Setting Secondary care in Denmark between 2003...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lund, Søren S, Tarnow, Lise, Frandsen, Merete, Nielsen, Bente B, Hansen, Birgitte V, Pedersen, Oluf, Parving, Hans-Henrik, Vaag, Allan A
Formato:	Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2009
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2775102/ https://www.ncbi.nlm.nih.gov/pubmed/19900993 http://dx.doi.org/10.1136/bmj.b4324

Ejemplares similares

Effect of Adjunct Metformin Treatment in Patients with Type-1 Diabetes and Persistent Inadequate Glycaemic Control. A Randomized Study
por: Lund, Søren Søgaard, et al.
Publicado: (2008)

Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus—the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial
por: Lundby-Christensen, Louise, et al.
Publicado: (2016)

Effects of biphasic, basal-bolus or basal insulin analogue treatments on carotid intima-media thickness in patients with type 2 diabetes mellitus: the randomised Copenhagen Insulin and Metformin Therapy (CIMT) trial
por: Lundby-Christensen, Louise, et al.
Publicado: (2016)

The T-Allele of TCF7L2 rs7903146 Associates With a Reduced Compensation of Insulin Secretion for Insulin Resistance Induced by 9 Days of Bed Rest
por: Alibegovic, Amra C., et al.
Publicado: (2010)

Hypolipidaemic and Insulin Secretagogue Activities of (R)-(−)-Carvone
por: Abbas, Manal Ahmad, et al.
Publicado: (2020)

Contribution of Mitochondria to Insulin Secretion by Various Secretagogues
por: Ježek, Petr, et al.
Publicado: (2022)

A prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia (the HypoAna trial): study rationale and design
por: Kristensen, Peter Lommer, et al.
Publicado: (2012)

Long-Term Effectiveness and Safety of Once Weekly Dulaglutide as Add-on to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
por: Mirabelli, Maria, et al.
Publicado: (2021)

Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study
por: Ciresi, Alessandro, et al.
Publicado: (2017)

Antihyperglycemic and Insulin Secretagogue Activities of Abrus precatorius Leaf Extract
por: Umamahesh, Balekari, et al.
Publicado: (2016)

Berberine is an insulin secretagogue targeting the KCNH6 potassium channel
por: Zhao, Miao-Miao, et al.
Publicado: (2021)

Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues
por: Vaag, Allan, et al.
Publicado: (2012)

Author Correction: Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study
por: Ciresi, Alessandro, et al.
Publicado: (2018)

THERAPY OF ENDOCRINE DISEASE: Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues
por: Vaag, Allan, et al.
Publicado: (2012)

Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
por: Mirabelli, Maria, et al.
Publicado: (2021)

Circulating adipokines data associated with insulin secretagogue use in breast cancer patients
por: Wintrob, Zachary A.P., et al.
Publicado: (2016)

A Novel Diphenylthiosemicarbazide Is a Potential Insulin Secretagogue for Anti-Diabetic Agent
por: Sugawara, Kenji, et al.
Publicado: (2016)

Author Correction: Berberine is an insulin secretagogue targeting the KCNH6 potassium channel
por: Zhao, Miao-Miao, et al.
Publicado: (2021)

Impact of 9 Days of Bed Rest on Hepatic and Peripheral Insulin Action, Insulin Secretion, and Whole-Body Lipolysis in Healthy Young Male Offspring of Patients With Type 2 Diabetes
por: Alibegovic, Amra C., et al.
Publicado: (2009)

Metformin may adversely affect orthostatic blood pressure recovery in patients with type 2 diabetes: substudy from the placebo-controlled Copenhagen Insulin and Metformin Therapy (CIMT) trial
por: Hansen, Christian Stevns, et al.
Publicado: (2020)

Correction: A Novel Diphenylthiosemicarbazide Is a Potential Insulin Secretagogue for Anti-Diabetic Agent
Publicado: (2017)

Association Between Serious Hypoglycemia and Calcium-Channel Blockers Used Concomitantly With Insulin Secretagogues
por: Nam, Young Hee, et al.
Publicado: (2021)

Interprofessional Continuous Glucose Monitoring for Underserved Adults with Type 2 Diabetes on Insulin or Secretagogues
por: Fasina, Ife, et al.
Publicado: (2021)

Glinide, but Not Sulfonylurea, Can Evoke Insulin Exocytosis by Repetitive Stimulation: Imaging Analysis of Insulin Exocytosis by Secretagogue-Induced Repetitive Stimulations
por: Aoyagi, Kyota, et al.
Publicado: (2009)

Circulating growth factors data associated with insulin secretagogue use in women with incident breast cancer
por: Wintrob, Zachary A.P., et al.
Publicado: (2017)

Insulin secretagogue use and circulating inflammatory C–C chemokine levels in breast cancer patients
por: Wintrob, Zachary A.P., et al.
Publicado: (2017)

Dataset on granulopoiesis- and lymphopoiesis-stimulating cytokine levels in insulin secretagogue users with incident breast cancer
por: Wintrob, Zachary A.P., et al.
Publicado: (2017)

Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes—a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study
por: Dejgaard, Thomas Fremming, et al.
Publicado: (2015)

The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design
por: Agesen, Rikke Mette, et al.
Publicado: (2019)

DNA methylation and gene expression of HIF3A: cross-tissue validation and associations with BMI and insulin resistance
por: Main, Ailsa Maria, et al.
Publicado: (2016)

TH1 and TH2 cytokine data in insulin secretagogues users newly diagnosed with breast cancer
por: Wintrob, Zachary A.P., et al.
Publicado: (2017)

Does DNA Methylation of PPARGC1A Influence Insulin Action in First Degree Relatives of Patients with Type 2 Diabetes?
por: Gillberg, Linn, et al.
Publicado: (2013)

Plasma Growth Differentiation Factor-15 Independently Predicts All-Cause and Cardiovascular Mortality As Well As Deterioration of Kidney Function in Type 1 Diabetic Patients With Nephropathy
por: Lajer, Maria, et al.
Publicado: (2010)

Correction: Does DNA Methylation of PPARGC1A Influence Insulin Action in First Degree Relatives of Patients with Type 2 Diabetes?
por: Gillberg, Linn, et al.
Publicado: (2013)

Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels
por: Sigalos, John T., et al.
Publicado: (2017)

Serum Uric Acid as a Predictor for Development of Diabetic Nephropathy in Type 1 Diabetes: An Inception Cohort Study
por: Hovind, Peter, et al.
Publicado: (2009)

Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial
por: Gæde, Peter, et al.
Publicado: (2016)

Assessing the Effect of Incretin Hormones and Other Insulin Secretagogues on Pancreatic Beta-Cell Function: Review on Mathematical Modelling Approaches
por: Pacini, Giovanni, et al.
Publicado: (2022)

Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomized, controlled, open‐label, crossover trial
por: Pedersen‐Bjergaard, Ulrik, et al.
Publicado: (2021)

Vitamin D Levels and Mortality in Type 2 Diabetes
por: Joergensen, Christel, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_omb2qtish66hljso54rfdnsucs